共载黄芪甲苷 IV 与雷帕霉素的骨髓间充质干细胞来源外泌体纳米载体靶向调控肝细胞癌 PI3K/Akt/mTOR 通路
Astragaloside IV and rapamycin co-loaded bone marrow mesenchymal stem cell-derived exosome nanocarriers for targeted modulation of the PI3K/Akt/mTOR p
RAP@AST-IV/EXO NC 通过联合抑制 PI3K/Akt/mTOR 和诱导线粒体凋亡,代表了一种有前景且具有生物相容性的靶向 HCC 治疗策略。
